Dyno founder and CEO Eric Kelsic stated: “This new collaboration with Roche, focused on developing next-generation gene ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

Roche has inked a new deal with Dyno Therapeutics to develop next-generation AAV capsids for gene therapies targeting ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Matica Biotechnology Inc. (Matica Bio), a CDMO specializing in viral vector development and manufacturing, announced the ...

New strategic partnership leverages the power of Dyno’s platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets ...